United Kingdom

People: Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

9:02pm BST
Change (% chg)

$0.27 (+0.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Dolsten, Mikael 

Dr. Mikael Dolsten, M.D., Ph.D., is the President - Worldwide Research and Development of the Company. He has been President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research & Development Group from October 2009 until May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. He was a Private Equity Partner at Orbimed Advisors, LLC from January 2008 until June 2008. Director of Karyopharm Therapeutics Inc. Chairman of the Translational Advisory Board of Apple Tree Partners from 2016 to 2017.

Basic Compensation

Total Annual Compensation, USD 2,632,250
Restricted Stock Award, USD 2,013,090
Long-Term Incentive Plans, USD --
All Other, USD 2,424,860
Fiscal Year Total, USD 7,070,200

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ian Read


Albert Bourla


Frank D'Amelio


Mikael Dolsten


Michael Goettler


Angela Hwang

As Of  31 Dec 2018